Business Context and Reporting Period
Company: Mustang Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 10, 2023
Reporting Period: Event-based report regarding the termination of a material definitive agreement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on the termination of a licensing agreement.
Material Changes
- Termination of UCLA License Agreement: On July 10, 2023, the Company terminated the Exclusive License Agreement dated March 17, 2017, with the Regents of the University of California (UCLA).
- Reason for Termination: The termination follows the Company's decision to discontinue development of its MB-105 (PSCA) program, which was previously announced on May 17, 2023, alongside the termination of a related agreement with the City of Hope.
- Technology Scope: The terminated agreement covered an exclusive license for prostate stem cell antigen (PSCA) chimeric antigen receptor (CAR) engineered T cell (CAR T) technology used in treating prostate cancer, pancreatic cancer, and other solid tumors.
- Effective Date: The termination is effective 30 days from the date of the notice.
Guidance, Outlook, and Risks
- Financial Impact: The Company will not incur any early termination penalties associated with the termination of the UCLA License Agreement.
- Strategic Shift: The discontinuation of the MB-105 program indicates a strategic pivot away from this specific PSCA CAR T technology pipeline.
- Reference: Full details of the agreement are referenced in the Company's Form 10-Q filed on August 14, 2017.
Key Facts for Investor Verification
- Confirm the Company has no outstanding financial obligations or penalties related to the terminated UCLA agreement.
- Verify the status of the Company's remaining clinical pipeline following the discontinuation of the MB-105 program.
- Review the May 17, 2023, disclosure regarding the termination of the City of Hope agreement for context on the broader program discontinuation.